<DOC>
	<DOC>NCT00651508</DOC>
	<brief_summary>The purpose of this study is to determine the Objective Response Rate of KOS-1584, as a single agent in patients with stage IIIB/IV NSCLC whose disease has progressed following initial chemotherapy.</brief_summary>
	<brief_title>Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Histologically or cytologically proven NSCLC, Stage IIIB or Stage IV. Eligible patients must have received only one prior chemotherapy regime for Stage IIIB/IV NSCLC. Good performance status. Prior treatment with an epothilone. Known central nervous system (CNS) metastases. Any chemotherapy, radiation therapy or immunotherapy or any investigational agent (therapeutic or diagnostic) within 3 weeks prior to first study drug administration.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Patients with Advanced or Metastatic stage IIIB/IV Non-Small Cell Lung Cancer</keyword>
</DOC>